{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:05Z","timestamp":1792787825559,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cipla Ltd., India"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world data on safety and clinical outcomes of remdesivir in COVID-19 management is scant. We present findings of data analysis conducted for assessing the safety and clinical outcomes of remdesivir treatment for COVID-19 in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis used data from an active surveillance programme database of hospitalised patients with COVID-19 who were receiving remdesivir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 2329 patients included, 67.40% were men. Diabetes (29.69%) and hypertension (20.33%) were the most common comorbidities. At remdesivir initiation, 2272 (97.55%) patients were receiving oxygen therapy. Remdesivir was administered for 5\u00a0days in 65.38% of patients. Antibiotics (64.90%) and steroids (47.90%) were the most common concomitant medications. Remdesivir was overall well tolerated, and total 119 adverse events were reported; most common were nausea and vomiting in 45.40% and increased liver enzymes in 14.28% patients. 84% of patients were cured\/improved, 6.77% died and 9.16% showed no improvement in their clinical status at data collection. Subgroup analyses showed that the mortality rate was significantly lower in patients\u2009&lt;\u200960\u00a0years old than in those\u2009&gt;\u200960\u00a0years old. Amongst patients on oxygen therapy, the cure\/improvement rate was significantly higher in those receiving standard low-flow oxygen than in those receiving mechanical ventilation, non-invasive ventilation, or high-flow oxygen. Factors that were associated with higher mortality were age\u2009&gt;\u200960\u00a0years, cardiac disease, diabetes high flow oxygen, non-invasive ventilation and mechanical ventilation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our analysis showed that remdesivir is well tolerated and has an acceptable safety profile. The clinical outcome of cure\/improvement was 84%, with a higher improvement in patients\u2009&lt;\u200960\u00a0years old and on standard low-flow oxygen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-07004-8","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T04:03:53Z","timestamp":1641269033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-2416","authenticated-orcid":false,"given":"Vaishali","family":"Gupte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabil","family":"Kalathingal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Malabade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Gogtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"1","key":"7004_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.23750\/abm.v91i1.9397","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157\u201360. https:\/\/doi.org\/10.23750\/abm.v91i1.9397.","journal-title":"Acta Biomed"},{"key":"7004_CR2","unstructured":"WHO Coronavirus (COVID-19) Dashboard. URL: https:\/\/covid19.who.int\/. Accessed 02 June 2021."},{"key":"7004_CR3","doi-asserted-by":"crossref","unstructured":"Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science. 2020. https:\/\/www.sciencemag.org\/news\/2020\/03\/who-launches-global-megatrial-four-most-promising-coronavirus-treatments. Accessed 17 March 2021.","DOI":"10.1126\/science.abb8497"},{"key":"7004_CR4","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-4-14","author":"J Pardo","year":"2020","unstructured":"Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020. https:\/\/doi.org\/10.7573\/dic.2020-4-14.","journal-title":"Drugs Context."},{"issue":"3","key":"7004_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269\u201371. https:\/\/doi.org\/10.1038\/s41422-020-0282-0.","journal-title":"Cell Res"},{"key":"7004_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.15.043166","author":"BN Williamson","year":"2020","unstructured":"Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.15.043166.","journal-title":"bioRxiv."},{"key":"7004_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.31.017889","author":"A Pizzorno","year":"2020","unstructured":"Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.31.017889.","journal-title":"bioRxiv."},{"issue":"7","key":"7004_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/ijp.IJP_486_20","volume":"52","author":"D Singh","year":"2020","unstructured":"Singh D, Wasan H, Mathur A, Gupta YK. Indian perspective of remdesivir: a promising COVID-19 drug. Indian J Pharmacol. 2020;52(7):227\u20138. https:\/\/doi.org\/10.4103\/ijp.IJP_486_20.","journal-title":"Indian J Pharmacol"},{"issue":"11","key":"7004_CR9","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, Arribas L\u00f3pez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048\u201357. https:\/\/doi.org\/10.1001\/jama.2020.16349.","journal-title":"JAMA"},{"issue":"19","key":"7004_CR10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","volume":"383","author":"JD Goldman","year":"2020","unstructured":"Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2015301.","journal-title":"N Engl J Med"},{"issue":"19","key":"7004_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19\u2014preliminary report. N Engl J Med. 2020;383(19):1813\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"N Engl J Med"},{"key":"7004_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1041","author":"SA Olender","year":"2020","unstructured":"Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa1041.","journal-title":"Clin Infect Dis"},{"issue":"24","key":"7004_CR13","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2007016.","journal-title":"N Engl J Med"},{"issue":"10229","key":"7004_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3.","journal-title":"Lancet"},{"issue":"11","key":"7004_CR15","doi-asserted-by":"publisher","first-page":"ofaa481","DOI":"10.1093\/ofid\/ofaa481","volume":"7","author":"G Lapadula","year":"2020","unstructured":"Lapadula G, Bernasconi DP, Bellani G, Soria A, Rona R, Bombino M, et al. Remdesivir use in patients requiring mechanical ventilation due to COVID-19. Open Forum Infect Dis. 2020;7(11):ofaa481. https:\/\/doi.org\/10.1093\/ofid\/ofaa481.","journal-title":"Open Forum Infect Dis"},{"key":"7004_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.05.20226373","author":"RM Mehta","year":"2020","unstructured":"Mehta RM, Bansal S, Bysani S, Kalpakam H. A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: a real-world analysis. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.11.05.20226373.","journal-title":"medRxiv."},{"issue":"4","key":"7004_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.dsx.2020.05.018","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020;14(4):641\u20138. https:\/\/doi.org\/10.1016\/j.dsx.2020.05.018.","journal-title":"Diabetes Metab Syndr"},{"key":"7004_CR18","unstructured":"US Food and Drug Administration. FDA\u2019s approval of Veklury (remdesivir) for the treatment of COVID-19\u2014The Science of Safety and Effectiveness. October 22, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness. Accessed 17 March 2021."},{"key":"7004_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00485-0","author":"F Ader","year":"2021","unstructured":"Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021. https:\/\/doi.org\/10.1016\/S1473-3099(21)00485-0.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"7004_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for COVID-19\u2014interim WHO Solidarity trial results. N Engl J Med. 2021;384(6):497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184.","journal-title":"N Engl J Med"},{"issue":"4","key":"7004_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2187","volume":"31","author":"HK Elsawah","year":"2021","unstructured":"Elsawah HK, Elsokary MA, Abdallah MS, ElShafie AH. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2021;31(4): e2187. https:\/\/doi.org\/10.1002\/rmv.2187.","journal-title":"Rev Med Virol"},{"issue":"2","key":"7004_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.7326\/M20-5752","volume":"174","author":"TJ Wilt","year":"2021","unstructured":"Wilt TJ, Kaka AS, MacDonald R, Greer N, Obley A, Duan-Porter W. Remdesivir for adults with COVID-19: a living systematic review for American college of physicians practice points. Ann Intern Med. 2021;174(2):209\u201320. https:\/\/doi.org\/10.7326\/M20-5752.","journal-title":"Ann Intern Med"},{"issue":"10239","key":"7004_CR23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","volume":"395","author":"MJ Cummings","year":"2020","unstructured":"Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(20)31189-2.","journal-title":"Lancet"},{"key":"7004_CR24","unstructured":"Simon Collins, HIV i-Base. Predictors of response to remdesivir in GS-5773 COVID-19 study. 2020. https:\/\/i-base.info\/htb\/38476. Accessed 17 March 2021."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-07004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-07004-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-07004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T04:07:01Z","timestamp":1641269221000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-07004-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7004"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-07004-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no need for administrative permissions, since it was mandatory for all hospitals and clinics that administered remdesivir in COVID-19 patients to provide data (through an active surveillance form) thus, obtaining ethical approval and informed consent was not required. As a part of regulatory approval, Cipla Ltd has to provide the data report to Central Drugs Standard Control Organisation (CDSCO) periodically. The data were anonymised before its use.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors are permanent employees of Cipla Ltd., India who had a role in the study. The study was funded by Cipla Ltd., India, and was the provider of the drug.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}